Concord Biotech Limited announced on June 10, 2026, that it has received Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration (USFDA) for its Tofacitinib Tablets in 5 mg and 10 mg strengths. These tablets are indicated for treating various autoimmune conditions, including rheumatoid arthritis and psoriatic arthritis. This approval signifies a substantial opportunity in the U.S. market, estimated at approximately US$ 500 million.
USFDA Approval for Tofacitinib Tablets
Concord Biotech Limited has officially announced its achievement of Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration (USFDA). The approval pertains to the company’s Tofacitinib Tablets, available in both 5 mg and 10 mg strengths. This significant regulatory milestone was communicated to the stock exchanges on June 10, 2026.
Therapeutic Applications and Market Opportunity
Tofacitinib Tablets are prescribed for adult patients managing a range of moderately to severely active autoimmune conditions. These include rheumatoid arthritis (RA), active psoriatic arthritis (PsA), active ankylosing spondylitis (AS), and active ulcerative colitis (UC). The approval also covers active polyarticular course juvenile idiopathic arthritis (pcJIA). The U.S. market for Tofacitinib Tablets, across both strengths, is estimated to be worth approximately US$ 500 million, presenting a considerable growth avenue for Concord Biotech.
Strategic Impact and Future Growth
This USFDA approval is strategically positioned to enable Concord Biotech to leverage attractive market opportunities within the United States. It is expected to enhance the company’s existing product portfolio and significantly contribute to its long-term growth strategy. The company views this as a key step in strengthening its presence in both U.S. and international markets.
Regulatory Disclosure Details
In accordance with regulatory requirements, the following details have been provided:
Regulatory Authority: U.S. Food & Drug Administration (USFDA)
Approval Details: Approval for Tofacitinib Tablets, 5 mg and 10 mg.
Impact on Listed Entity: The approval aligns with Concord Biotech’s growth strategy and is expected to strengthen its position in the U.S. market.
Withdrawal/Cancellation/Suspension: Not Applicable.
Validity Period: Not Applicable.
Monetary Impact: Not Applicable.
Source: BSE
